Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emblem Corp EMMBF

Healthcare Biotechnology Cannabis
"Emblem Corp is a licensed producer of medical cannabis. It is intended to cultivate and cure cannabis for medicinal use. The group operates in the business segment of production and sale of medical cannabis."


OTCPK:EMMBF - Post by User

Emblem Corp > who is selling at these prices
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by deminimison Mar 02, 2018 10:34pm
145 Views
Post# 27655292

RE:RE:RE:RE:RE:who is selling at these prices

RE:RE:RE:RE:RE:who is selling at these pricesCanopy sells capsules for 10.5/gram, Medreleaf sells them for 16/gram. Based on the pricing of other products I suspect the capsules that Emblem will start selling in the summer will be priced closer to Medreleaf. These will just be the oils they are currently selling in a capsule form.

The sustained release formulation that is due out next year will likely be able to command a higher price point although Emblem's cut will probably end up being less once they start selling through pharmacies.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities